Vital Signs - Next-Generation Sequencing Services Market: An Expanding Role in Clinical Applications Opens New Markets

 

Regular Price: USD 1,500

Special Price USD 1,125

25% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,125

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on March 30, 2012, provides a strategic insight on the next-generation sequencing services market.

Additionally, a company spotlight is provided for Foundation Medicine. Founded in 2010, the cancer diagnostics firm aims to transform cancer care by including comprehensive molecular analysis of tumors from next-generation sequencing to the diagnostic process. Reimbursement and regulatory news from the FDA is also provided for week of March 12, 2012.

Table of Contents

Vital Signs - Next-Generation Sequencing Services Market: An Expanding Role in Clinical Applications Opens New MarketsVital Signs: March 30 2012This week's issue




Related Research

Release Date : 19-Sep-17

Region : North America

Release Date : 08-Sep-17

Region : North America

Release Date : 22-Aug-17

Region : North America

Release Date : 08-Aug-17

Region : North America

Release Date : 31-Jul-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.